Editing Antidepressant (section)

===Serotonin modulators and stimulators===
[[Serotonin modulator and stimulator]]s (SMSs), sometimes referred to more simply as "[[serotonin]] modulators", are a type of [[drug]] with a multimodal action specific to the serotonin [[neurotransmitter]] system. To be precise, SMSs simultaneously modulate one or more [[serotonin receptor]]s and inhibit the [[reuptake]] of serotonin. The term was coined in reference to the [[mechanism of action]] of the serotonergic antidepressant [[vortioxetine]], which acts as a [[serotonin reuptake inhibitor]] (SRI), a [[partial agonist]] of the [[5-HT1A receptor|5-HT<sub>1A</sub> receptor]], and [[receptor antagonist|antagonist]] of the [[5-HT3 receptor|5-HT<sub>3</sub>]] and [[5-HT7 receptor|5-HT<sub>7</sub> receptor]]s.<ref name="pmid24391391">{{cite journal|author=Goldenberg MM|title=Pharmaceutical approval update|journal=P T|volume=38|issue=11|pages=705–7|date=November 2013|pmid=24391391|pmc=3875258}}</ref><ref name="AmerPharmAssoc2013">{{cite web|url=http://www.pharmacist.com/vortioxetine-atypical-antidepressant|author=American Pharmacists Association|title=Vortioxetine: Atypical antidepressant|year=2013|url-status=live|archive-url=https://web.archive.org/web/20151120095834/http://www.pharmacist.com/vortioxetine-atypical-antidepressant|archive-date=20 November 2015}}</ref><ref name="LATimes2013">{{cite web|url=https://www.latimes.com/science/sciencenow/la-sci-fda-approval-antidepressant-20130930-story.html|title=FDA approves a new antidepressant: Brintellix|website=Los Angeles Times|year=2013|url-status=live|archive-url=https://web.archive.org/web/20151120162327/http://www.latimes.com/science/sciencenow/la-sci-fda-approval-antidepressant-20130930-story.html|archive-date=20 November 2015}}</ref> However, it can also technically be applied to [[vilazodone]], which is an antidepressant as well and acts as an SRI and 5-HT<sub>1A</sub> receptor partial agonist.<ref name="pmid15740724">{{cite journal|vauthors=Hughes ZA, Starr KR, Langmead CJ, etal|title=Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone|journal=European Journal of Pharmacology|volume=510|issue=1–2|pages=49–57|date=March 2005|pmid=15740724|doi=10.1016/j.ejphar.2005.01.018}}</ref>

An alternative term is serotonin partial agonist/reuptake inhibitor (SPARI), which can be applied only to vilazodone.<ref>{{cite book|vauthors=Stahl SM|others=with illustrations by Muntner N|title=Stahl's essential psychopharmacology : neuroscientific basis and practical application|date=2013|publisher=Cambridge University Press|location=Cambridge|isbn=978-1107686465|edition=4th}}</ref>